Article
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation - Bone Marrow Transplantation
Rating:
0.0
Views:
26
Likes:
1
Library:
1
Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative treatment for myelofibrosis (MF). Relapse occurs in 10–30% and remains a major factor for dismal outcomes. Previous work suggested that graft-versus-host disease (GVHD) might be associated with risk of relapse. This study included 341 patients undergoing their first (n = 308) or second (n = 33) alloHSCT.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value